| Date | Title | Description |
| 09.09.2026 | Dragon Boat teams smash fundraising target with £50,000+ raised for new Cambridge Cancer Research Hospital | This year's Cambridge Dragon Boat Festival saw a day of firsts, a day of celebrations and a day of coming together to remember why everyone involved was taking part.
At what marked the festival's 20th year, the 43 teams that took part smash... |
| 05.08.2026 | Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey | Expedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.
The round was led by General Atlantic, with fellow new investors R... |
| 12.06.2026 |
Jim Cramer says SpaceX’s blockbuster IPO could have major implications for the week ahead | Monday - Friday, 6:00 - 7:00 PM ET
CNBC’s Jim Cramer said the successful debut of SpaceX could pave the way for more AI-related offerings and help create a more constructive backdrop for stocks.
He said investors should watch housing starts... |
| 23.03.2026 | Stocks making the biggest moves midday: Palantir, Flutter, United Airlines, Synopsys, Insmed & more | - |
| 09.10.2025 | Expedition resupplies for phase 2 COPD voyage with $165M series A | Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstruct... |
| 09.07.2025 |
Cramer’s Lightning Round: No to Ouster | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Insmed: ”...That one is very speculative. I... |
| 10.06.2025 | Wall Street ends higher as investors track US-China trade talks | Wall Street ends higher as investors track US-China trade talks
By Noel Randewich and Sukriti GuptaJune 10, 20258:40 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 Traders work on t... |
| 10.06.2025 | Stocks making the biggest moves midday: Topgolf Callaway, Insmed, J.M. Smucker, SolarEdge & more | - |
| 09.06.2025 | Stocks tick higher as investors await details on U.S.-China trade talks progress: Live updates | Stocks edged higher Tuesday as investors waited for more insight on trade discussions between the U.S. and China.
The Dow Jones Industrial Average added 82 points, or 0.2%. The S&P 500 rose around 0.3% along with the Nasdaq Composite.
T... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 19.10.2022 | Insmed Announces Strategic Financings Totaling $775 Million | - |
| 28.10.2021 | Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update | BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the ... |
| 19.05.2021 | Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference | |
| 13.05.2021 | Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes | |
| 13.05.2021 | INSMED INCORPORATED
Insmed Incorporated : Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters' Options to Purchase Additional Shares a... | BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the "Equity Offering") of 11,500,000 shares of its... |
| 11.05.2021 | INSMED INCORPORATED
Insmed Incorporated : Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 | BRIDGEWATER, N.J., May 11, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the "Shares") at a price to the ... |
| 23.03.2021 | ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficientl... | BRIDGEWATER, N.J., March 23, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Japan's Ministry of... |
| 05.03.2021 | Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | BRIDGEWATER, N.J., March 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of induceme... |
| 25.02.2021 | Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update | BRIDGEWATER, N.J., Feb. 25, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the ... |
| 19.02.2021 | Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP) | |
| 04.01.2021 | Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease | |
| 02.12.2020 | Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis | |
| 13.11.2020 | Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) | |
| 28.10.2020 | European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Trea... | |
| 07.09.2020 | New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis | |
| 27.06.2012 | Insmed Announces First Patient Dosed in TARGET-NTM Phase 2 Clinical Trial of ARIKACE® in Patients with Non-Tuberculous Mycobacteria (NTM) Lung Disease | MONMOUTH JUNCTION, N.J., June 27, 2012 /PRNewswire/ — Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company’s U.S. phase 2 clinical study of ARIKACE® (liposo... |
| 07.05.2012 | Cystic fibrosis lung infection drug trial gets OK’d after FDA lifts clinical hold | The FDA halted patient recruitment for a phase 3 clinical trial for patients with pseudomonas aeruginosa lung infections in August last year after a parallel trial with rats produced a lung tumor in two rats. It had also suspended clinical ... |
| 11.10.2011 | Azelon secures $4.5 million in Series A funding, restructures company | The financing has prompted a restructuring of the company, formerly called Zelos Therapeutics.
Don Hayden has been appointed executive chairman and Joan Lau has been named president and CEO. Lau succeeds Brian MacDonald, who will remain wit... |
| - | Insmed to Present at Two March Conferences | BRIDGEWATER, N.J., Feb. 24, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will par... |
| - | Azelon secures $4.5 million in Series A funding, restructures company | Azelon Pharmaceuticals in West Conshohocken, Pennsylvania, has received $4.5 million in Series A financing from three venture capital firms to develop its nasal spray formulation of teriparatide for the treatment of osteoporosis.
Palo Alto,... |
| - | Cystic fibrosis lung infection drug trial gets OK’d after FDA lifts clinical hold | The U.S. Food and Drug Administration agreed to lift a clinical hold on a mid- to late-stage drug to treat cystic fibrosis patients for two different types of lung infections nine months after invoking it.
Insmed’s (NASDAQ CM:INSM) Arikace ... |
